The Medicines and Healthcare products Regulatory Agency Delivery Plan 2021-2023

This plan follows closely on the back of some of the new powers and changes laid down in the new ‘Medicines and Medical Devices Act 2021’ (March 2021) which now allows for updates to be made to the UK life sciences regimen. This plan also provides something tangible after all the noises emerging from MHRA over the last few years.

The MHRA say they intend to become a “world-leading, innovative regulator” and “become a global exemplar in public health and patient safety, enabled through regulation and at the forefront of innovation”.

The Medicines and Healthcare products Regulatory Agency Delivery Plan 2021-2023

Devices Update

Be aware that a new (UK) Medical Devices legislative framework will soon emerge. This is intended to make provision for quicker assessment routes for innovation and to facilitate disruptive technologies reaching the market in shorter timeframe. And to also make the UK appear to be a more attractive place for assessment and launch into world markets. There is also an obvious need to address the (UK specific) requirements for an “updated adverse event reporting and medical device safety surveillance system that is more responsive that detects and responds to signals of issues more quickly and enables greater interaction with reporters”. In Europe this is known as EUDAMED.